

Martin Metzenmacher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/189249/publications.pdf>

Version: 2024-02-01

22
papers

333
citations

1162889

8
h-index

839398

18
g-index

24
all docs

24
docs citations

24
times ranked

626
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined multimodal ctDNA analysis and radiological imaging for tumor surveillance in Non-small cell lung cancer. <i>Translational Oncology</i> , 2022, 15, 101279.	1.7	7
2	Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications. <i>Lung Cancer</i> , 2022, 168, 10-20.	0.9	6
3	A Role for PET/CT in Response Assessment of Malignant Pleural Mesothelioma. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 816-823.	2.5	5
4	The clinical utility of <scp>cfRNA</scp> for disease detection and surveillance: A proof of concept study in non-€small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 2180-2191.	0.8	4
5	Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V600-mutated Squamous Cell Lung Cancer: Concurrent Evolvement of PTEN and MEK1 Mutations. <i>Clinical Lung Cancer</i> , 2021, 22, e668-e672.	1.1	4
6	Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant Mesothelioma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 191-194.	2.8	10
7	Prognostic Value of Postinduction Chemotherapy Volumetric PET/CT Parameters for Stage IIIA or IIIB Non-€Small Cell Lung Cancer Patients Receiving Definitive Chemoradiotherapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1684-1691.	2.8	5
8	BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy. <i>European Journal of Cancer</i> , 2021, 149, 211-221.	1.3	9
9	Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma. <i>Future Oncology</i> , 2021, 17, 3965-3976.	1.1	6
10	Patterns of nodal spread in stage III NSCLC: importance of EBUS-TBNA and 18F-FDG PET/CT for radiotherapy target volume definition. <i>Radiation Oncology</i> , 2021, 16, 176.	1.2	6
11	Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation. <i>Lung Cancer</i> , 2020, 139, 165-168.	0.9	4
12	Machine learning reveals a PD-L1-€independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context. <i>European Journal of Cancer</i> , 2020, 140, 76-85.	1.3	30
13	ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 149, 10-16.	0.9	7
14	Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer. <i>Cancers</i> , 2020, 12, 353.	1.7	24
15	Lower-dosing ponatinib in pre-treated GIST: Results of the POETIG phase II trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11536-11536.	0.8	3
16	Impact of RAS mutation subtype on clinical outcome-€a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer. <i>Oncogene</i> , 2019, 38, 2953-2966.	2.6	38
17	Platelet number and graft function predict intensive care survival in allogeneic stem cell transplantation patients. <i>Annals of Hematology</i> , 2019, 98, 491-500.	0.8	11
18	MET Expression in Advanced Non-€Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy. <i>Clinical Lung Cancer</i> , 2018, 19, e441-e463.	1.1	61

#	ARTICLE	IF	CITATIONS
19	Phosphorylation of p70 Ribosomal Protein S6 Kinase $\hat{2}$ -1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e331-e352.	1.0	13
20	Sarcomatoid carcinoma of the lung: a rare histological subtype of non-small cell lung cancer with a poor prognosis even at earlier tumour stages. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2017, 24, iw392.	0.5	29
21	Thoracic staging with 18F-FDG PET/MR in non-small cell lung cancer – does it change therapeutic decisions in comparison to 18F-FDG PET/CT?. <i>European Radiology</i> , 2017, 27, 681-688.	2.3	49
22	Efficacy and safety of nivolumab combined with standard therapies for first-line therapy of advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, E1254-E1256.	0.6	0